Search results
Results from the WOW.Com Content Network
It was approved by the FDA in March 2017 [33] and is reported to cost $37,000 per year. [3] Kevzara (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment of adults with rheumatoid arthritis approved by the FDA in May 2017. [34] Trials commenced in March 2020 to evaluate the effectiveness of Kevzara in the treatment ...
New data showing Zolgensma’s substantial benefits for presymptomatic children made the drug cost-effective at prices up to $1.9 million by one benchmark and up to $2.1 million by another, it said.
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. [6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.
Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count. [21] Low neutrophil counts may occur with HIV/AIDS , following chemotherapy or radiation poisoning , or be of an unknown cause. [ 21 ]
Nvidia (NASDAQ: NVDA) and other AI stocks plunged on Monday, Jan. 27, as investors responded to the threat from DeepSeek, the Chinese AI chatbot that rivals top models like ChatGPT for a fraction ...
Within the year of 2014, the cost of prescriptions had increased by at least 11.4% and 58% within the last eight years. The average cost for a month supply of brand-name drugs can run up to a couple of hundred US dollars, whereas in Canada and Great Britain the same medication could cost up to $40 US dollars.
Drugmaker Novo Nordisk later got approval to market Wegovy, a semaglutide that has a different dosage, for weight loss. The drugs have been in short supply since 2022, soon after the FDA approved ...
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute ...